Jakub Tolar, M.D., Ph.D.
Dr. Tolar is an Associate Professor of Pediatrics at the University of Minnesota in the Division of Blood and Marrow Transplantation, and an attending physician at the University of Minnesota Amplatz Children’s Hospital – Fairview. Dr. Tolar is trained both in basic science and in medicine. He received his M.D. from Charles University in Prague, Czech Republic, and his Ph.D. in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota. He completed a residency in Pediatrics and a fellowship in hematology/oncology and bone marrow transplantation at the University of Minnesota. He is board certified in Pediatric Hematology/Oncology. Dr. Tolar has been the Director of Stem Cell/Gene Therapies in the Division of Blood and Marrow Transplantation since 2011.
Dr. Tolar's research focuses on stem cell therapy for patients with lethal diseases—cancer, inborn errors of metabolism, and devastating genetic disorders.
In the laboratory, he is currently working on inducing pluripotency in a variety of cell types and creating human disease models “in a dish” at the cellular level. He is also investigating gene editing using sequence-specific nucleases. Dr. Tolar’s primary motivation is improving patient care and the clinical translation of tissue stem cell and regenerative biology. He has several clinical trials that focus on the efficacy and safety of new treatments for diseases like epidermolysis bullosa and dyskeratosis congenita. He also leads the International Fanconi Anemia Gene Therapy Working Group.
Selected Recent Publications
Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J. N Engl J Med. 2010;363(7):629-39.
Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.
Tolar J, Xia L, Riddle M, Lees CJ, Eide C, McElmurry RT, Titeux M, Osborn MJ, Lund TC, Hovnanian A, Wagner JE, Blazar BR. J Invest Dermatol. 2011;131(4):848-56.
Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).
Tolar J, Park IH, Xia L, Lees CJ, Peacock B, Webber B, McElmurry RT, Eide CR, Orchard PJ, Kyba M, Osborn MJ, Lund TC, Wagner JE, Daley GQ, Blazar BR. Blood. 2011;117(3):839-47.
Synthetic zinc finger nuclease design and rapid assembly.
Osborn MJ, Defeo AP, Blazar B, Tolar J. Hum Gene Ther. 2011 Sep;22(9):1155-65.
Sarcoma derived from cultured mesenchymal stem cells.
Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PCW, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR. Stem Cells. 2007;25(2):371-9.
Gene therapy for Fanconi anemia: one step closer to the clinic.
Tolar J, Becker PS, Clapp DW, Hanenberg H, de Heredia CD, Kiem HP, Navarro S, Qasba P, Rio P, Schmidt M, Sevilla J, Verhoeyen E, Thrasher AJ, Bueren J. Hum Gene Ther. 2012;23(2):141-4.
Hematopoietic cell transplantation for nonmalignant disorders.
Tolar J, Mehta PA, Walters MC. Biol Blood Marrow Transplant. 2012;18(1 Suppl):S166-71.